ZA969016B - Solubilisation methods. - Google Patents
Solubilisation methods.Info
- Publication number
- ZA969016B ZA969016B ZA9609016A ZA969016A ZA969016B ZA 969016 B ZA969016 B ZA 969016B ZA 9609016 A ZA9609016 A ZA 9609016A ZA 969016 A ZA969016 A ZA 969016A ZA 969016 B ZA969016 B ZA 969016B
- Authority
- ZA
- South Africa
- Prior art keywords
- solubilisation
- methods
- solubilisation methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9521805.3A GB9521805D0 (en) | 1995-10-25 | 1995-10-25 | Solubilisation methods |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA969016B true ZA969016B (en) | 1998-04-28 |
Family
ID=10782854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9609016A ZA969016B (en) | 1995-10-25 | 1996-10-25 | Solubilisation methods. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0857061A1 (en) |
JP (1) | JP2000502990A (en) |
KR (1) | KR19990067028A (en) |
CN (1) | CN1202818A (en) |
AU (1) | AU704292B2 (en) |
BR (1) | BR9611343A (en) |
CA (1) | CA2235487A1 (en) |
GB (1) | GB9521805D0 (en) |
NO (1) | NO981864L (en) |
NZ (1) | NZ320442A (en) |
WO (1) | WO1997015289A1 (en) |
ZA (1) | ZA969016B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605709D0 (en) * | 1996-03-19 | 1996-05-22 | Cortecs Ltd | Method |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
DK2240155T3 (en) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Devices, formulations and methods for the delivery of several beneficial agents |
LT2462246T (en) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | IMMEDIATE IMPLEMENTATION AND / OR TERMINATION OF IMMEDIATE STATIONARY SUPPLY |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012115A1 (en) * | 1978-12-04 | 1980-06-11 | Ciba-Geigy Ag | Pharmaceutical compositions for topical treatment of virus infections |
US4411882A (en) * | 1978-12-21 | 1983-10-25 | Sandoz Ltd. | Galenical compositions |
-
1995
- 1995-10-25 GB GBGB9521805.3A patent/GB9521805D0/en active Pending
-
1996
- 1996-10-25 AU AU73178/96A patent/AU704292B2/en not_active Ceased
- 1996-10-25 CA CA002235487A patent/CA2235487A1/en not_active Abandoned
- 1996-10-25 BR BR9611343-0A patent/BR9611343A/en not_active Application Discontinuation
- 1996-10-25 ZA ZA9609016A patent/ZA969016B/en unknown
- 1996-10-25 EP EP96935083A patent/EP0857061A1/en not_active Withdrawn
- 1996-10-25 NZ NZ320442A patent/NZ320442A/en unknown
- 1996-10-25 KR KR1019980702965A patent/KR19990067028A/en not_active Application Discontinuation
- 1996-10-25 CN CN96198527A patent/CN1202818A/en active Pending
- 1996-10-25 WO PCT/GB1996/002609 patent/WO1997015289A1/en not_active Application Discontinuation
- 1996-10-25 JP JP9516406A patent/JP2000502990A/en active Pending
-
1998
- 1998-04-24 NO NO981864A patent/NO981864L/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1997015289A1 (en) | 1997-05-01 |
AU704292B2 (en) | 1999-04-15 |
GB9521805D0 (en) | 1996-01-03 |
NO981864D0 (en) | 1998-04-24 |
BR9611343A (en) | 1999-12-28 |
KR19990067028A (en) | 1999-08-16 |
CA2235487A1 (en) | 1997-05-01 |
NO981864L (en) | 1998-06-24 |
AU7317896A (en) | 1997-05-15 |
NZ320442A (en) | 1999-10-28 |
EP0857061A1 (en) | 1998-08-12 |
JP2000502990A (en) | 2000-03-14 |
CN1202818A (en) | 1998-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA967315B (en) | Biphenylamides. | |
MX213417B (en) | Phenylpyridazinones. | |
ZA9710429B (en) | Broad-spectrumδ-endotoxins. | |
ZA979199B (en) | Aminothiophenecarboxamides. | |
ZA976168B (en) | 3-Ureido-pyridofurans and -pyridothiophenes. | |
ZA964468B (en) | Triazolylmethyl-cyclopentanols. | |
ZA977206B (en) | Arylalkanoylpyridazines. | |
ZA961955B (en) | Indazolecarboxamides. | |
ZA978304B (en) | 3-alkyl-3-phenyl-piperidines. | |
MXPA99002581A (en) | Dredging apparatus. | |
ZA969016B (en) | Solubilisation methods. | |
DE69610844D1 (en) | Hydroformylierungsverfahren. | |
ZA969625B (en) | 25-Hydroxy-16-ene-26, 27-bishomo-cholecalciferols | |
ZA966603B (en) | Therapeutic method. | |
ZA966399B (en) | Endothelin-receptor-antagonists. | |
ZA97572B (en) | 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines. | |
ZA976022B (en) | Cycloalkano-pyridines. | |
ZA966933B (en) | Endothelin-receptor-antagonists. | |
ZA966750B (en) | Halogenobenzimidazoles. | |
ZA971466B (en) | Endothelin-receptor-antagonists. | |
ZA967314B (en) | Carbamoylcarboxamides. | |
ZA966699B (en) | Substituted 2-phenylpyridines. | |
ZA969560B (en) | Substituted 1-methyl-3-phenylpyrazoles. | |
ZA971474B (en) | Endothelin-receptor-antagonists. | |
ZA968953B (en) | 24-homo-26,27-hexafluoro-cholecalciferols |